Correlation Between Integrated Biopharma and TSS, Common

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Integrated Biopharma and TSS, Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Integrated Biopharma and TSS, Common into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Integrated Biopharma and TSS, Common Stock, you can compare the effects of market volatilities on Integrated Biopharma and TSS, Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Integrated Biopharma with a short position of TSS, Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Integrated Biopharma and TSS, Common.

Diversification Opportunities for Integrated Biopharma and TSS, Common

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Integrated and TSS, is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Integrated Biopharma and TSS, Common Stock in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on TSS, Common Stock and Integrated Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Integrated Biopharma are associated (or correlated) with TSS, Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of TSS, Common Stock has no effect on the direction of Integrated Biopharma i.e., Integrated Biopharma and TSS, Common go up and down completely randomly.

Pair Corralation between Integrated Biopharma and TSS, Common

If you would invest (100.00) in Integrated Biopharma on December 29, 2024 and sell it today you would earn a total of  100.00  from holding Integrated Biopharma or generate -100.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

Integrated Biopharma  vs.  TSS, Common Stock

 Performance 
       Timeline  
Integrated Biopharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Integrated Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Integrated Biopharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
TSS, Common Stock 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days TSS, Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Integrated Biopharma and TSS, Common Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Integrated Biopharma and TSS, Common

The main advantage of trading using opposite Integrated Biopharma and TSS, Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Integrated Biopharma position performs unexpectedly, TSS, Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TSS, Common will offset losses from the drop in TSS, Common's long position.
The idea behind Integrated Biopharma and TSS, Common Stock pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Complementary Tools

Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Stocks Directory
Find actively traded stocks across global markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format